T2 Biosystems, Inc. TTOO is a Buy, Again
TTOO is a Buy, Again. The ups and downs of TTOO, like many penny stocks, can be volatile and difficult to predict. However, there are some patterns that can be observed in the stock's price movements. The ups and downs of TTOO are almost like clockwork and we are approaching BUY time again.
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the T2Biothreat™ Panel. The FDA 510(k) clearance allows the company to immediately begin marketing and selling the T2Biothreat Panel in the U.S. market.
The T2Biothreat Panel is a direct-from-blood molecular diagnostic test that runs on the FDA-cleared T2Dx® Instrument and simultaneously detects six biothreat pathogens, including the organisms that cause anthrax (Bacillus anthracis), tularemia (Francisella tularensis), glanders (Burkholderia mallei), melioidosis (Burkholderia pseudomallei), plague (Yersinia pestis), and typhus (Rickettsia prowazekii). These pathogens have been identified as threats by the U.S. Centers for Disease Control and Prevention and identified as material biological threats under section 319-2(c)(2)(A)(ii) of the Public Health Service Act.
The T2Biothreat Panel is the first and only FDA-cleared product able to simultaneously detect these six high-priority biothreat pathogens, and the only FDA-cleared multi-target biothreat product developed and manufactured by a U.S. owned company.
About T2 Biosystems
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, the T2Bacteria® Panel, the T2Candida® Panel, the T2Resistance® Panel, the T2Biothreat™ Panel, and the T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the T2Cauris™ Panel, and T2Lyme™ Panel, as well as next-generation products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers. For more information, please visit www.t2biosystems.com.
NIST Graded Our Post-Quantum Cryptography. Zero Failures.
NIST's Algorithm Validation Test System generated test vectors nobody had seen, we answered them over the ACVP protocol, and NIST graded the result: 2,130 cases across ML-KEM, ML-DSA and SLH-DSA in every parameter set offered, zero failures, demo certificate A11025. This is what that proves, where we deliberately drew the claim narrower than NIST's own matrix, and why the FIPS 140-2 sunset on 21 September makes the distinction between being graded and grading yourself worth understanding.
The Problem Is Not the Problem
People treat the Jack Sparrow line as a joke. The attribution is a joke. The sentence is not. Forty years in markets says the same thing Epictetus said in 125 CE and Robert Merton named in 1948: the event is finite, and the story you appoint to govern it is not. This essay walks the quote back to its actual sources, draws the loop that turns a feeling into an order, and sets out the four places a rule written in advance cuts the loop. Faith is not a hedge. It is a stance.
What KXCO Is, and Why the Hard Problem Was Never Intelligence
The prevailing enthusiasm assumes the hard problem is intelligence. It is not. It is that banks, hospitals, courts and governments are being asked to let software act on their behalf with no way to establish who decided, on what basis, or whether the record will still read in a decade. KXCO founder Shayne Heffernan sets out the architecture that answers those questions, drawn as a graph, and argues that properly constructed AI is an amplifier of human judgement rather than a replacement for it.
Earnings, the Economic Calendar and Trading Strategies: September 8 to 12, 2026
A four-session week decides more than a print. Oracle reports after the close on Thursday 10 September, PPI lands that morning and CPI on Friday, with the ECB in between and the FOMC eight days out. Oracle is the last hyperscaler of the cycle and the widest value gap on the KXCO Ontology Live Analyst Outlook layer: a $457bn market value under a $638bn contracted backlog. Here is the calendar, the graph behind it, the levels and the book.
Every story, signed and delivered.
Subscribe to the kxco channel and get the headline, the AI-written key takeaways, and the chain-anchor link the moment we publish. Audio versions and per-ticker subscriptions arrive in the next iteration.